Dr. Sam Hanna

Dermatologist, Toronto, ON

Sam Hanna
Dermatologist, Toronto, ON

Dr. Hanna grew up in Toronto but completed his medical and dermatology specialty training in the US. He practiced there for almost a decade before returning home to Toronto to establish his Dermatology practice. Dr. Hanna has been practicing medical, aesthetic and investigational dermatology for over 20 years.
He has been principal investigator in over 40 clinical trials in aesthetic and medical indications.
He is the Medical Director of Dermatology on Bloor, a large single-specialty dermatology practice in downtown Toronto. He is adjunct clinical faculty in the Division of Dermatology, Department of Medicine at the University of Toronto where he serves as co-lead for Undergraduate Medical Education.
Dr. Hanna is past-president of the Toronto Dermatological Society, serves on the OMA section of Dermatology Board and has been secretary of the Canadian Dermatology Association and chaired many committees there.

3:45 PM - 4:35 PM

NOV 2 (Thu)

Navigating the Skincare Maze: A Scientific Guide to Choosing the Right Products for the right patients

Navigating the ever-evolving skincare landscape to recommend the most effective products to patients can often feel like maneuvering through a maze. This open session aims to serve as a guide to help physicians make informed choices rooted in scientific evidence.
This dynamic session will delve deep into the latest advances in dermatological science, examining the published studies and clinical evidence surrounding antioxidants and retinoids in skincare. The goal is to shed light on the pivotal role these ingredients play in promoting skin health and addressing various skin concerns. Dr. Sam Hanna and Dr. Sonya Abdulla will bring their clinical expertise to explore the art and science of selecting the right products that best cater to individual patient needs.
Join this session to enhance your understanding of the latest developments in the skincare field and learn practical tips for making informed, scientifically-backed choices in product recommendations for patients.

1:05 PM - 1:55 PM

NOV 3 (Fri)

Seb D or Not to B? That is the Clinical Question


  1. Analyze and review the current understanding of the pathogenesis involved in seborrheic dermatitis
  2. Discuss the heterogenous clinical presentations of seborrheic dermatitis and other similar inflammatory/pruritic skin conditions
  3. Examine the benefits and challenges of current treatment options for seborrheic dermatitis and explore future treatment options

Summary Description: Join us on a Shakespearean exploration where the many facets of seborrheic dermatitis will be brought to the stage. In the opening act, our expert moderator/director, Dr. Sam (Hamlet) Hanna, will review our present understanding on the multifactorial pathogenesis of this common chronic inflammatory condition. In the following acts, our expert speakers, Dr. Melinda Gooderham, Dr. Daniel Wong, and Dr. Geeta Yadav, will discuss varying clinical points of perspective on the commonalities and differences between seborrheic dermatitis and other inflammatory/pruritic skin conditions with respect to the pathophysiology and clinical presentations. This open session will also examine the efficacy, safety, and tolerability of current topical treatments. The final act will explore new developments in topical treatment for seborrheic dermatitis. Those in attendance at the theatre will gain a better understanding of the treatment strategies and unmet needs in the management of patients with this common chronic inflammatory dermatosis.

3:00 PM - 3:50 PM

NOV 3 (Fri)

Unmet Needs in Atopic Dermatitis: Towards a Mechanistic Understanding


  1. Describe the burden of uncontrolled atopic dermatitis in different patient populations
  2. Summarise recent translational discovery underlying itch, and the pathophysiology and phenotypes of AD

There are unmet needs in the management of atopic dermatitis (AD), especially in underserved areas. Itch is the most universal symptom in patients with AD and is typically the most burdensome symptom. When asked about the frequency of itch in 110 patients with AD in Canada surveyed by CSPA and Eczema Quebec, over 70% mentioned that they experienced itch everyday in the past week. With recent translational discoveries, there have been substantial advances in the understanding of the phenotypes of AD, the sensation of itch and its molecular pathways from skin to brain. This Open Session will review the burden of uncontrolled AD in different patient populations, the molecular mechanisms underlying the pathophysiology of AD and the sensation of itch.